Filing Details

Accession Number:
0000950170-24-015944
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-15 16:33:43
Reporting Period:
2024-01-01
Accepted Time:
2024-02-15 16:33:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661998 Homology Medicines Inc. FIXX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1586226 Arthur Tzianabos C/O Homology Medicines, Inc.
One Patriots Park
Bedford MA 01730
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-01 14,280 $0.00 122,675 No 4 M Direct
Common Stock Acquisiton 2024-01-01 19,140 $0.00 141,815 No 4 M Direct
Common Stock Disposition 2024-01-09 13,037 $0.57 128,778 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-01-01 14,280 $0.00 14,280 $0.00
Common Stock Restricted Stock Units Disposition 2024-01-01 19,140 $0.00 19,140 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
19,720 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
  2. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
  3. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5710 to $0.5712. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
  4. The RSUs are fully vested and do not have an expiration date.
  5. The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date.